UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

Annals of oncology, 2011-01, Vol.22 (1), p.39-48

2011

Volltextzugriff (PDF)

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis

Blood cancer journal (New York), 2015-08, Vol.5 (8), p.e335-e335

2015

Volltextzugriff (PDF)

The Signature Program: Bringing the Protocol to the Patient

Clinical pharmacology and therapeutics, 2015-08, Vol.98 (2), p.124-126

2015

Volltextzugriff (PDF)

P1044: REAL‐WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA

HemaSphere, 2022-06, Vol.6 (Suppl), p.934-935

2022

Volltextzugriff (PDF)

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Annals of oncology, 2009-11, Vol.20 (11), p.1794-1802

2009

Volltextzugriff (PDF)

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m(2) 24 h or 1.3 mg/m(2) 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Annals of oncology, 2009-11, Vol.20 (11), p.1794

2009

Volltextzugriff (PDF)

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

Annals of oncology, 2011-01, Vol.22 (1), p.49-58

2011

Volltextzugriff (PDF)

The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models

European journal of cancer (1990), 2022-10, Vol.174, p.S57-S58

2022

Volltextzugriff (PDF)

A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas

Annals of oncology, 2018-03, Vol.29, p.iii7-iii7

2018

Volltextzugriff (PDF)

42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas

Annals of oncology, 2018-03, Vol.29 (suppl_3)

2018

Volltextzugriff (PDF)

9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age

European journal of cancer supplements, 2009, Vol.7 (2), p.590-591

2009

Volltextzugriff (PDF)

S831 CPI‐0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO‐INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS

HemaSphere, 2019-06, Vol.3 (S1), p.369-n/a

2019

Volltextzugriff (PDF)

5034 POSTER Pharmacokinetics of trabectedin in women with recurrent ovarian cancer

European journal of cancer supplements, 2007, Vol.5 (4), p.321-321

2007

Volltextzugriff (PDF)

7517 POSTER Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced/metastatic liposarcoma or leiomyosarcoma (L-sarcomas) progressing despite prior treatment with at least anthracycline and ifosfamide

European journal of cancer supplements, 2007, Vol.5 (4), p.407-407

2007

Volltextzugriff (PDF)

Influence of tumor control on tumor-related events (TRE) in relapsed ovarian cancer (ROC): Results from OVA-301, a randomized phase III study of trabectedin (Tr) with pegylated liposomal doxorubicin (PLD) versus PLD alone

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.e15529-e15529

2010

Volltextzugriff (PDF)

Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.5012-5012

2010

Volltextzugriff (PDF)

Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.1010-1010

2009

Volltextzugriff (PDF)

Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.5551-5551

2009

Volltextzugriff (PDF)

Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma

Drugs of Today, 2009-06, Vol.45 (6), p.403

2009

Volltextzugriff (PDF)

Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.5579-5579

2007

Volltextzugriff (PDF)

Combination of trabectedin (T) and doxorubicin (D) for the treatment of patients with soft tissue sarcoma (STS): Safety and efficacy analysis

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.10078-10078

2007

Volltextzugriff (PDF)

Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.2080-2080

2006

Volltextzugriff (PDF)

Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors

Journal of clinical oncology, 2006-06, Vol.24 (18_suppl), p.2029-2029

2006

Volltextzugriff (PDF)

Long-term weekly paclitaxel over 1 hour infusion with limited premedication. A phase II trial report

European journal of cancer (1990), 1999-09, Vol.35, p.S326-S326

1999

Volltextzugriff (PDF)

Nail disorders in patients treated with weekly paclitaxel (P)

European journal of cancer (1990), 1999-09, Vol.35, p.S379-S379

1999

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(69)

Sprache

Englisch
(45)
Französisch
(24)

Erscheinungsjahr

n.n

Thema

Science & Technology
(18)
Life Sciences & Biomedicine
(16)
Humans
(10)
Radiology
(9)
Adult
(6)
Aged
(6)
Female
(6)
Middle Aged
(6)
Oncology
(6)
Aged, 80 And Over
(5)
Dioxoles - Adverse Effects
(5)
Original
(5)
Tetrahydroisoquinolines - Adverse Effects
(5)
Trabectedin
(5)
Antineoplastic Agents, Alkylating - Adverse Effects
(4)
Dioxoles - Administration & Dosage
(4)
Male
(4)
Medicine
(4)
Microbiology
(4)
Pharmacology & Pharmacy
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial

A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis

The Signature Program: Bringing the Protocol to the Patient

P1044: REAL‐WORLD RUXOLITINIB TREATMENT PATTERN IN MYELOFIBROSIS PATIENTS WITH THROMBOCYTOPENIA

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m(2) 24 h or 1.3 mg/m(2) 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval

The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models

A phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas

42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas

9402 Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age

S831 CPI‐0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) INHIBITOR, REDUCES PRO‐INFLAMMATORY CYTOKINES, BONE MARROW FIBROSIS AND THE NUMBER OF TRANSFUSIONS IN MYELOFIBROSIS PATIENTS

5034 POSTER Pharmacokinetics of trabectedin in women with recurrent ovarian cancer

7517 POSTER Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced/metastatic liposarcoma or leiomyosarcoma (L-sarcomas) progressing despite prior treatment with at least anthracycline and ifosfamide

Influence of tumor control on tumor-related events (TRE) in relapsed ovarian cancer (ROC): Results from OVA-301, a randomized phase III study of trabectedin (Tr) with pegylated liposomal doxorubicin (PLD) versus PLD alone

Extending platinum-free interval (PFI) in partially platinum-sensitive (PPS) patients (pts) with recurrent ovarian cancer (ROC) treated with trabectedin (Tr) plus pegylated liposomal doxorubicin (Tr+PLD) versus PLD alone: Results from a PPS cohort of a phase III study

Preliminary safety and activity results of trabectedin in a phase II trial dedicated to triple-negative (ER-, PR-, HER2-), HER2+++, or BRCA1/2 germ-line-mutated metastatic breast cancer (MBC) patients (pts)

Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: An exploratory analysis in the ova-301 phase III study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD

Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma

Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies

Combination of trabectedin (T) and doxorubicin (D) for the treatment of patients with soft tissue sarcoma (STS): Safety and efficacy analysis

Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder

Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors

Long-term weekly paclitaxel over 1 hour infusion with limited premedication. A phase II trial report

Nail disorders in patients treated with weekly paclitaxel (P)

Suchergebnisse filtern